TY  - GEN
AU  - Robson,Mark
AU  - Ruddy,Kathryn J
AU  - Im,Seock-Ah
AU  - Senkus,Elżbieta
AU  - Xu,Binghe
AU  - Domchek,Susan M
AU  - Masuda,Norikazu
AU  - Li,Wei
AU  - Tung,Nadine
AU  - Armstrong,Anne
AU  - Delaloge,Suzette
AU  - Bannister,Wendy
AU  - Goessl,Carsten
AU  - Degboe,Arnold
AU  - Hettle,Robert
AU  - Conte,Pierfranco
TI  - Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
SN  - 1879-0852
PY  - 2020///0609
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - BRCA1 Protein
KW  - genetics
KW  - BRCA2 Protein
KW  - Biomarkers, Tumor
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Capecitabine
KW  - administration & dosage
KW  - Female
KW  - Follow-Up Studies
KW  - Furans
KW  - Germ-Line Mutation
KW  - Humans
KW  - International Agencies
KW  - Ketones
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Patient Reported Outcome Measures
KW  - Phthalazines
KW  - Piperazines
KW  - Prognosis
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Survival Rate
KW  - Time-to-Treatment
KW  - Vinorelbine
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ejca.2019.06.023
ER  -